Guardant Health (NASDAQ:GH) Director Sells $20,300.00 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $20,300.00. Following the completion of the sale, the director owned 11,449 shares of the company’s stock, valued at approximately $2,003,575. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $156.45, for a total value of $18,148.20.
• On Monday, June 22nd, Musa Tariq sold 1,951 shares of Guardant Health stock. The stock was sold at an average price of $131.16, for a total value of $255,893.16.

Guardant Health Stock Performance

Guardant Health stock traded up $8.20 during mid-day trading on Thursday, reaching $183.10. The stock had a trading volume of 1,858,277 shares, compared to its average volume of 2,252,181. The firm has a market capitalization of $24.57 billion, a PE ratio of -52.46 and a beta of 1.57. Guardant Health, Inc. has a fifty-two week low of $55.38 and a fifty-two week high of $183.51. The stock’s 50-day simple moving average is $160.33 and its 200-day simple moving average is $126.47.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The firm had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. During the same quarter in the prior year, the business earned ($0.44) earnings per share. Guardant Health’s revenue for the quarter was up 44.3% on a year-over-year basis. On average, research analysts forecast that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on GH shares. BTIG Research reiterated a “buy” rating and set a $195.00 price objective on shares of Guardant Health in a report on Wednesday, September 2nd. Barclays raised their price target on shares of Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Evercore reiterated an “outperform” rating and set a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. UBS Group increased their price objective on Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, Canaccord Genuity Group raised their target price on Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $188.12.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors have recently added to or reduced their stakes in GH. Revere Asset Management Inc purchased a new stake in Guardant Health in the 2nd quarter valued at about $3,994,000. Sequoia Financial Advisors LLC bought a new position in shares of Guardant Health in the second quarter valued at approximately $216,000. First Light Asset Management LLC increased its position in shares of Guardant Health by 57.5% during the second quarter. First Light Asset Management LLC now owns 441,586 shares of the company’s stock valued at $66,251,000 after acquiring an additional 161,287 shares during the last quarter. Tidal Investments LLC increased its position in shares of Guardant Health by 43.7% during the second quarter. Tidal Investments LLC now owns 24,593 shares of the company’s stock valued at $3,690,000 after acquiring an additional 7,473 shares during the last quarter. Finally, MCF Advisors LLC lifted its holdings in Guardant Health by 755.0% during the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock worth $26,000 after acquiring an additional 151 shares during the period. 92.60% of the stock is owned by institutional investors.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant Health was described as nearing a technical buy point as its sales outlook brightened, supporting investor confidence in continued revenue growth. Guardant Health Nears Buy Point As Sales Outlook Brightens
• Positive Sentiment: A comparison of second-quarter testing and diagnostics companies highlighted Guardant Health’s strong performance. The company’s revenue rose 44.3% year over year to approximately $335 million and exceeded analyst expectations, while its quarterly loss was narrower than forecast. Testing & diagnostics services stocks Q2 results: Benchmarking Guardant Health
• Positive Sentiment: The stock reached a new one-year high, reflecting strong momentum and investor demand following its recent rally. The move could attract additional momentum-oriented buyers, though it also raises the risk of profit-taking. Guardant Health Reaches New 1-Year High – What’s Next?
• Neutral Sentiment: Director Musa Tariq sold 116 shares for about $20,300, reducing his position by 1%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, making it a limited and less concerning signal. SEC Form 4 filing
• Negative Sentiment: Several insiders reported sales: Director Alex M. Azar II sold 826 shares for approximately $144,550, Director Steve Krognes sold 6,674 shares for roughly $1.17 million, and CTO Darya Chudova sold 7,738 shares for about $1.38 million. The transactions reduced their holdings substantially and could raise profit-taking concerns, although the sales were disclosed through SEC filings and some were conducted under pre-arranged plans. Insider sale SEC filing

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.